On February 4, 2021 Lantheus Holdings, Inc. (NASDAQ: LNTH) (the "Company"), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, reported three abstracts featuring its PSMA-targeted pipeline of product candidates have been selected for poster presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary (ASCO GU) Virtual Meeting, which will be held from February 11-13, 2021 (Press release, Lantheus Medical Imaging, FEB 4, 2021, View Source [SID1234574637]). Two of the abstracts relate to PyL, the Company’s PET/CT imaging agent for prostate cancer, and the third abstract relates to 1095, the Company’s radiopharmaceutical therapeutic for metastatic castration resistant prostate cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations will be made available for the duration of conference.
Details for the ASCO (Free ASCO Whitepaper) GU presentations based on Company-sponsored studies are as follows:
Date & Time: February 11, 2021, 8:00 AM-6:30 PM ET
Session Title: Poster Session: Prostate Cancer – Advanced Disease
Title: A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Presenter: Jeremy C. Durack, M.D., M.S., Memorial Sloan Kettering Cancer Center
Abstract No: 32
Date & Time: February 11, 2021, 8:00 AM-6:30 PM ET
Session Title: Poster Session: Prostate Cancer – Advanced Disease
Title: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR) – A sub analysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Presenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Québec-Université Laval
Abstract No: 33
Date & Time: February 11, 2021, 8:00 AM-6:30 PM ET
Session Title: Trials in Progress Poster Session: Advanced Prostate Cancer
Title: A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
Presenter: Oliver Sartor, M.D., Tulane Cancer Center
Abstract No: TPS187